Ora

Ora Biomedical is a private, preclinical-stage biotech founded in 2018 and based in San Diego. The company has developed a proprietary, automated discovery engine called WormBot-AI, which combines robotics, computer vision, and machine learning to screen millions of molecules for longevity and healthspan effects in the model organism C. elegans. This high-throughput, in vivo approach is designed to uncover subtle therapeutic effects missed by traditional in vitro methods. Ora is currently leveraging this platform to identify and develop novel interventions, positioning itself at the intersection of geroscience, AI-driven drug discovery, and translational medicine.

WormBot-AI: An integrated platform combining robotics, computer vision, and deep learning for fully automated, high-throughput drug screening and phenotypic analysis in live C. elegans. It quantifies lifespan, healthspan, and behavioral metrics to discover longevity and resilience-enhancing interventions.

Ora competes in the longevity drug discovery space with other geroscience startups (e.g., Unity Biotechnology, Calico Life Sciences, Altos Labs) and AI-driven discovery platforms. Its differentiation lies in its specific focus on automated, high-throughput in vivo screening in C. elegans and its open-science 'Million Molecule Challenge' initiative.